Table 2.
Immune responses immediately post-vaccination.
| ZyCoV-D | INO-4800 | COVID-eVax | AG0302 | GX-19N | GLS-5310 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose (mg) > Device > Schema (wks) > |
1 mg Inj 0–4–8 |
1 mg NFIS 0–4–8 |
2 mg Inj 0–4–8 |
2 mg NFIS 0–4–8 |
1 mg 3P 0–4 |
2 mg 3P 0–4 |
2 mg ClinEP 0–4 |
0.4 mg Pyro-jet 0–2 |
3.0 mg Elimtek 0–4 |
0.6 mg GD 0–8 |
1.2 mg GD 0–8 |
1.2 mg GD 0–12 |
| Binding antibody end point titer | 39 | 96 | 748 | 884 | 331.2 | 691.4 | 6 IU/mL | 324.9 | 201.6 | 708.0 | 645.5 | 241.4 |
| Responder | 36% | 33% | 100% | 80% | 74% | 100% | 80% | NR | 75% | 93% | 93% | 93% |
| Neutralizing antibody end point titer | 8.5 | 12.0 | 14.1 | 39.2 | 44.4 | 34.9 | 10 | 7.6 | 24 | 25 | 15 | 25 |
| Responder | 18% | 17% | 50% | 80% | 78% | 84% | 10% | NR | 100% | 33% | 73% | 60% |
| SFU/106 cells | 10 | 70 | 16 | 64 | 26.2 | 71.1 | 150 | 61.8 | 750 | 576 | 1090 | 482 |
| Responder | 100% | 100% | 100% | 100% | 74% | 100% | 90% | NR | 52% | 93% | 93% | 93% |
For ZyCoV-D, values are shown on study day 84, 1 month post-vaccination. T cell responses for the 1 mg injection-only group for ZyCoV-D were ~120 and 64 SFU/106 cells for the 1 mg NFIS group on day 56, whereas for other groups, maximal responses were observed at day 84. Baseline values for binding antibodies and neutralizing antibodies respectively, averaged 14.8 and 6.3 across groups. Baseline T cell responses averaged 11 SFU/106 cells. For INO-4800, values are shown for week 6, 2 weeks post-vaccination. Baseline titers for binding and neutralizing antibodies were 0 and 16, respectively. For COVD-eVax, values are shown for week 8, 4 weeks post-vaccination. Baseline antibody responses were not detected; baseline T cell responses averaged 50 SFU/106 cells. For AG0302, values are shown for week 4, 2 weeks post-vaccination. Baseline binding antibody responses were elevated with a titer of 324.9, whereas neutralizing antibody responses at baseline were 1.6 and T cell responses of 6 SFU/106 cells. For GX-19N, values are shown for day 57, 4 weeks post-vaccination for antibody responses and day 43 for T cell responses. Binding antibody responses at baseline were 24.4 and 20 for binding antibody and neutralizing antibody responses and 200 for T cell responses. For GLS-5310, values are shown for 4 weeks post-second vaccination. Baseline titers for binding and neutralization antibodies were non-reactive. Baseline values for T cell responses averaging 67 SFU/106 cells. Abbreviations: Inj, injection; NFIS, PharmaJet Tropis® needle-free injection system; 3P, Cellectra 2000-3P® electroporation device; ClinEP, Cliniporator electroporation device; GD, GeneDerm® suction device, NR, not reported.